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FOCUS ON TOBACCO
REGULATION AND
THE PUBLIC’S HEALTH
FROM THE DIRECTOR
The University of Maryland’s Law & Health Care Program has been part of
efforts to address the harmful effects of tobacco consumption. In 2001, the Program,
in conjunction with the School’s Environmental Law Program, was instrumental in
establishing the Legal Resource Center for Tobacco Regulation, Litigation and
Advocacy at the University of Maryland School of Law. The Center has been
involved in tobacco regulation initiatives at the local, state, national, and most
recently, international level. In this issue, we celebrate the Center’s Fifth
Anniversary and provide you with an update on what the Center has accomplished
over its first five years as well as its plans for the future.
It has been over fifty years since thetobacco industry faced its first lawsuitby a lung cancer victim alleging
negligence and breach of warranty (see
Pritchard v. Liggett & Myers Tobacco Co.)1 and
over forty years since the Surgeon General
released his report concluding that smoking
causes lung cancer.  Despite this passage of
time, tobacco remains one of the “least-
regulated consumer products in the
marketplace,”2 millions of Americans
continue to smoke, teenagers continue to
“join the army of the addicted in
disturbingly large numbers,”3 and tobacco
products still claim the lives of hundreds of
thousands of Americans each year. While
the initial efforts to control and regulate
tobacco were at the federal level, the
public health battle against tobacco
products is now being fought on four
levels of government: federal, state, local
and international.
In the 1960s, the primary efforts aimed at
regulating tobacco products were a result
of Congressional and federal agency actions.
After the Surgeon General’s Report in
1964, Congress passed the Federal Cigarette
Labeling and Advertising Act in 1965
requiring warnings on all cigarette packs.
Just two years later, in 1967, the FCC, after
litigation on the issue, applied the “fairness
doctrine” to cigarette advertisements
requiring broadcasters to balance cigarette
ads with antismoking advertisements.
Three years after that, via passage of the
Public Health Cigarette Smoking Act,
Congress banned all cigarette ads on radio
and television.
There was little regulatory action at
any level during the 1970s, with the
exception of a rule promulgated by the
Civil Aeronautics Board in 1973 that
airlines must create nonsmoking sections.
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There are a number of law school faculty
who contribute to the diversity of the Law
& Health Care Program through their
teaching and scholarship.
They include:
Richard Boldt, JD
Chris Bostic, JD
Irving Breitowitz, JD
Kathleen Hoke Dachille, JD
I. Michael Greenberger, JD
Deborah S. Hellman, JD, MA
Thomas Pérez, JD, MPP
Karen Rothenberg, JD, MPA
Lawrence Sung, JD, PhD
Allyn Taylor, JSD, LLM
Ellen M. Weber, JD
Deborah J. Weimer, JD, LLM
Robin F. Wilson, JD
Roger C. Wolf, JD
Adjunct Faculty (2006-2007)
Barbara Billauer, JD, Foundation for
Law and Science Centers, Inc.
Ellen Callegary, JD, Callegary and Steedman
Marc Charmatz, JD, National Assn. of the Deaf
James Doherty, Jr., JD, Pecore & Doherty, LLC
W. Lawrence Fitch, JD, Maryland Dept. of
Health and Mental Hygiene
Gail Javitt, JD, MPH, Phoebe R. Berman
Bioethics Institute, Johns Hopkins University
John Lessner, JD, Ober|Kaler
Janet Lord, LLB, LLM, LLM
Blue Law, LLC
Kevin McAnaney, JD, Law Office
of Kevin G. McAnaney
Lewis Noonberg, JD, DLA Piper
Lisa Ohrin, JD, Centers for Medicare and
Medicaid Services (CMS)
Robert T.M. Phillips, MD, PhD, Forensic
Consultation Association, Inc.
Frank Palumbo, PhD, JD, University of
Maryland School of Pharmacy
Jack Schwartz, JD, Maryland Office of the
Attorney General
Sanford Teplitzky, JD, Ober|Kaler
Program Coordinator
Virginia Rowthorn, JD
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The 1980s were a much more active
time for tobacco regulation. State and
local governments began to regulate
smoking in public places but also passed
laws protecting smokers from non-
discrimination.  At the federal level, in
1984, Congress passed the Comprehensive
Smoking Education Act strengthening
warnings on cigarette packages and ads,
and in 1986, the Surgeon General issued
his report on the harms associated with
secondhand smoke.
The decade of the nineties brought
several new approaches to tobacco
regulation at the state
and federal levels.
Following the passage
by California citizens
in 1988 of Proposition
99, a few states
approved increases in
cigarette taxes.  In
addition, the EPA
designated
environmental
tobacco smoke
(secondhand smoke)
as a Class A
carcinogen and
proposed regulation
of indoor air quality;
the FDA proposed
jurisdiction over marketing of cigarettes and
announced regulations aimed at restricting
youth access to tobacco products; and states
across the country filed suits against the
tobacco industry to recover Medicaid costs
associated with the treatment of patients for
smoking related illness. While the FDA was
not successful in its bid to regulate tobacco
as an addictive drug, the EPA, after a law
suit by the tobacco industry, was successful
in its efforts to regulate secondhand smoke.
Moreover, the Attorneys General of 46
states and 6 U.S. territories signed a $206
billion Master Settlement Agreement (MSA)
with the five largest tobacco manufacturers
(Brown & Williamson, Lorillard, Philip
Morris, R.J. Reynolds, Commonwealth
Tobacco, and Liggett & Myers). Four states
had previously settled with tobacco
manufacturers for $40 billion.4  The MSA
ended a “four-year legal battle between
the states and the industry that began in
1994 when Mississippi became the first
state to file suit.”5
The MSA settled all antitrust, consumer
protection, common law negligence,
statutory, common law and equitable
claims for monetary, restitutionary, and
injunctive relief alleged by each of the
settling states for violations of the law that
occurred in the year of payment or earlier.
Under the provisions of the agreement,
companies are exempt from future liability
from state governments for tobacco-
related Medicaid expenditures in
exchange for a combination
of yearly settlement payments
to the states and voluntary
restrictions on advertising and
marketing of tobacco
products.6
During the 2000s, the
effort to regulate tobacco
has continued, primarily at
the local and state levels and
at the international level.
States are taking a variety of
tacks to reduce the
deleterious effects of
secondhand smoke and to
reduce youth access to
smoking. A number of
states are using their portion
of funds received under the
MSA to support antismoking programs,
although some states have been criticized
for spending the funds on totally
unrelated activities.7 The trend to restrict
smoking in public places has continued
so that all 50 states and the District of
Columbia now have laws or policies
restricting smoking in certain places.
These laws vary considerably from state
to state with some simply requiring
designated smoking areas in government
buildings and others prohibiting smoking
in virtually all public places and
workplaces.  Nineteen states, the District
of Columbia, and Puerto Rico prohibit
smoking in all workplaces, restaurants
and bars.8  All 50 states and D.C. also
now impose an excise tax on cigarettes,
however these taxes range “from a high
of $2.575 per pack in New Jersey to a
low of $0.07 per pack in South
Carolina.”9  According to the American
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Lung Association’s web site on state
legislation on tobacco issues, the national
average for state cigarette excise taxes as
of April 1, 2007 was $1.02/pack.
All 50 states and the District of
Columbia also prohibit the sale of
tobacco products to minors. The laws
vary in terms of how “minor” is defined
and as to how the laws are enforced.
Twenty-six states require minors who
violate the youth access or smoking laws
to perform community service in addition
to, or in lieu of, a fine; nine states may
suspend the driver’s license of a minor
who violates their youth access law; 16
states require minors to attend smoking
education/cessation classes in addition to
or instead of other penalties. In order to
reduce youth access to tobacco products,
20 states also restrict customer access to
cigarettes and other tobacco products and
14 of those states totally prohibit
customers from having direct access to
tobacco products and/or have language
prohibiting the use of self-service displays.
Many states also restrict the sale of
tobacco products in vending machines.10
Newer areas of tobacco regulation at
the state and local level include
restrictions based on the harmful effects
of secondhand smoke. While some states
have made
significant progress
on banning smoking
in public places,
others still have
much to do in this
area.  A cutting
edge issue for states
and local
governments is
regulation of
smoking in private
places, such as cars
with children, foster homes, and
residential places, e.g., condos and
apartment buildings where individuals
live in close quarters and smoke from
one residential unit can drift to other
units.
Another new area of tobacco
regulation is legislation requiring that
cigarettes sold in a state be fire resistant
(or “fire safe”).  Such legislation has
passed in at least ten states and is being
considered in 19 states.11
Regulation at the International Level
The newest frontier for tobacco
regulation is at the global level.  In May
2003, the member states of the World
Health Organization agreed to the text of
the Framework Convention on Tobacco
Control (FCTC), the first public health
treaty. Although the World Health
Assembly unanimously approved the
treaty, the fractious nature of negotiations
leading up to approval of the treaty
highlight the potential hurdles to
successful implementation of treaty
provisions. The treaty requires countries
to “impose restrictions on tobacco
advertising, sponsorship and promotion;
establish new packaging and labeling of
tobacco products; establish clean indoor
air controls; and strengthen legislation to
clamp down on tobacco smuggling.”12
There are currently 168 signatories to the
treaty and 146 parties (member states who
have signed and ratified it).  The United
In 2001, Maryland’s General Assemblyestablished the Cigarette RestitutionFund (CRF) which serves as the
state’s depository for all revenues received
from the tobacco industry as a result of
the Master Settlement Agreement (MSA).
By law, the Cigarette Restitution Fund is
used to fund the state’s Tobacco Use
Prevention and Cessation Program; the
Cancer Prevention, Education, Screening,
and Treatment Program; and other state
programs that serve health, education, and
tobacco prevention purposes.  (As of
January, 2003, Maryland ranked fifteenth
among the 50 states and Washington, D.C.
in its use of the settlement funds for
tobacco-related health purposes.)
In 2001, in response to a proposal
drafted by University of Maryland
School of Law Professor Diane
Hoffmann, the state, through the CRF,
THE CENTER FOR TOBACCO REGULATION,
LITIGATION AND ADVOCACY–THE FIRST FIVE YEARS
provided the law school with funding to
establish the Legal Resource Center for
Tobacco Regulation, Litigation and
Advocacy (the “Center”). The Center
was created to provide expertise and
resources for community groups, state
and local legislatures and agencies, private
entities, and lawyers attempting to reduce
smoking and its related health impacts.
Getting Started
During the initial planning year for the
Center (2001-2002), Michael Strande, a
2001 School of Law graduate (now
Managing Director of the Center), met
with the Health Officer and tobacco staff
in each of Maryland’s 24 local jurisdictions
and with tobacco control advocacy groups
throughout Maryland to determine the
legal needs of the state’s tobacco control
community.  The voluminous “Needs
Assessment” created by Strande served as
the blueprint for the early operation of the
Center.  Initial activities of Center staff
included meeting with local health
department and community coalition
members to hear about their local needs,
drafting policies and legislation to meet
those needs, assisting local governments
obtain passage of local legislation, and
keeping the statewide community
informed about tobacco control policy
work in Maryland and across the country
with the publication of the bi-annual
newsletter, Tobacco Regulation Review, and
through the Center website,
www.law.umaryland.edu/tobacco.
In 2002, Kathleen Dachille, a 1992
School of Law graduate, was recruited to
join the School of Law faculty and to
become the Center’s Director. One of
Cont. on page 4
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Dachille’s first tasks was to start the
Tobacco Control Clinic, a part of the law
school’s clinical offerings providing
hands-on training to law students
interested in public health policy
development and implementation.
Through the clinic, which typically
enrolls ten students each year who work
on Center related projects, the Center
was able to expand its ability to serve the
tobacco control community.
The Center has made significant
inroads into tobacco control efforts
during the first five years of its operations.
Since its inauguration, Center staff has
Center provided litigation support to the
County Attorney’s Office in successfully
defending the case.  The Center also
provided legal assistance to other
jurisdictions in gaining passage of local
tobacco control laws, including a
Howard County prohibition against
giving away cigarettes and a Prince
George’s County law requiring that
cigarettes be sold only in packages of 20
or more.  In addition, the Center helped
several local jurisdictions including
Carroll, Frederick, Garrett, Harford, and
Kent Counties enforce a state law
prohibiting the sale of tobacco to minors.
At the state
level, the Center
has assisted
legislators gain
passage of tobacco
control bills before
the Maryland
General Assembly.
In 2005, the Center
celebrated the
passage of a law
that requires health
insurers to cover
the cost of certain
smoking cessation
medications and
doctors’ visits and a
law prohibiting the
sale of tobacco
through the
internet.  That
same year, the Center drafted and helped
usher through the General Assembly a
law requiring that tobacco products sold
in Carroll and Garrett Counties be placed
behind the counter, out of the
customer’s reach.
Significant effort on the part of the
Center toward the passage of the
Maryland Clean Indoor Air Act paid off
this year.  The bill, which prohibits
smoking in all public places and
workplaces (with certain limited
exceptions) and enhances and expands
current state regulations, passed the
Maryland General Assembly on the last
day of the 2007 session.  Governor
Martin O’Malley signed the bill, which
will go into effect on February 1, 2008.
This legislation will make Maryland the
19th state to have such a wide-reaching
ban on indoor smoking.
Another of the Center’s major
legislative victories is the Firefighter
Protection and Cigarette Fire Safety Act.
The law requires that cigarettes sold in
Maryland meet certain fire safety
standards designed to reduce accidental
fires caused by cigarettes.  Center staff
and clinic students assisted in drafting the
bill and the accompanying fiscal note,
provided written and oral testimony in
support of the bill to House and Senate
committees, and coordinated the
testimony of national fire safety experts.
In April, the Act passed the General
Assembly with a 136-1 vote in the House
and a 46-0 vote in the Senate.  Governor
O’Malley recently signed the bill which
will go into effect on July 1, 2008.
During the next legislative session, the
Center plans to continue to work with
state legislators on bills that would
increase the penalties to retailers who sell
tobacco to minors, protect foster children
from exposure to secondhand smoke, and
impose tobacco product placement
restrictions on all Maryland retailers.
Tobacco Center:  Work at the National
Level
The Center’s work is also expanding
on the national level.  Center Director
Dachille helped found and is currently a
Steering Committee member of the
Tobacco Control Legal Consortium
(TCLC), a national network created in
2002 to support tobacco control policy
change by giving advocates better access
to legal expertise.  TCLC grew out of a
collaboration among existing legal
programs serving six states, including
Maryland’s Tobacco Center, the
Technical Assistance Legal Center
(California), the Tobacco Control
Resource Center (Massachusetts), the
Tobacco Law Center (Minnesota),
Smokefree Environments Law Project
(Michigan), and the Tobacco Control
Policy Legal Resource Center (New
Jersey).  Recently, the TCLC added two
Center for Tobacco Regulation
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worked on many projects, big and small,
at the national, state, and local levels. This
year, the Center added international
tobacco policy work to its agenda (see
article, p. 7).
Tobacco Center:  Work at the Local and
State Levels
At the local level, the Center has
provided advice to several counties
considering the passage of clean indoor
air legislation prohibiting smoking in
restaurants and bars, areas left open by
the state smokefree workplace
regulations. After passage, one County’s
law (Montgomery County) was
subsequently challenged in court, and the
Tobacco Center Staff (l-r):
Megan McDonald, Michael Strande, Kathleen
Dachille, Erin Smith, Jacqueline McNamara
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CONFERENCE NEWS
“‘SAFER TOBACCO PRODUCTS’:
REDUCING HARM OR GIVING FALSE HOPE?”
Cont. on page 6
Camel cigarette’s iconicdromedary’s ears must have beenburning on Friday, April 20, as
the Law & Health Care Program and the
Center for Tobacco Regulation, Litigation
and Advocacy held the first national
conference on the issue of “reduced harm”
tobacco
products.
Central to the
discussion was
whether
Camel’s new,
fashionably
packaged chew
tobacco
product, Snus,
and other products like it have a role in the
fight against tobacco-related illnesses.  The
conference, “‘Safer Tobacco Products’:
Reducing Harm or Giving False Hope?,”
brought together key scientists, policy
makers and tobacco control advocates to
discuss this timely and immensely important
issue.  Unlike nicotine replacement
products, reduced harm tobacco products
are alternative tobacco-related sources of
nicotine, including smokeless tobacco
products such as chew and snuff, and
newly designed products such as the
Marlboro Ultrasmooth.  The primary issue
addressed by conference speakers and
attendees was whether these reduced harm
products have a place at the tobacco
control table, in other words, whether
tobacco control advocates should embrace
these products as a part of an overall
tobacco control framework or embrace a
policy of total abstinence from all tobacco
products.  An important related issue
discussed at the conference was whether
and how the federal and state
governments can and should regulate the
marketing and sale of such products.
Conference speakers traced the history
of reduced harm products spending
significant time on the public health
debacle of the “light” cigarette.  Mitch
Zeller, Vice President for Policy and
Strategic Communications at Pinney
Associates and former Executive V.P. of
the American Legacy Foundation,
reminded attendees that, when the
causal relationship between cigarette
smoking and lung cancer was first
established in the 1950s, the tobacco
industry began altering its products by
adding filters to cigarettes, and then, in
the 1960s, by marketing so-called “low
tar and low nicotine” cigarettes.
Twenty years later, after extensive
testing, researchers determined that
smokers who switched to light cigarettes
did not reduce their lung cancer risk.  In
addition, research has shown that
their perceptions of the safety of the new
Eclipse cigarette (a cigarette-like product
sold by R.J. Reynolds that heats rather
then burns tobacco to create an inhalable
vapor).  Twenty-four percent of
respondents believed that Eclipse reduced
the risk of using tobacco by 100% and
57% believed that it reduced the risk by
60-100%.  The danger of these consumer
assumptions is that they are based on
express or implied advertising claims rather
than on long-term scientific evidence –
evidence that neither R.J. Reynolds nor
the government has acquired on the
Eclipse product.
This wariness on the part of the
tobacco control community was echoed
by various speakers and is primarily a result
of two concerns:  (1) how reduced harm
products are marketed, and (2) suspicion
regarding the major cigarette industries’
inroads into the smokeless tobacco
market.  Several speakers voiced concern
that these products are being marketed to
young people – with advertisements that
feature concerts and “blondes” and flavors
such as “spice” and “frost.”  On another
front, Zeller voiced concern that the
products are marketed as “bridges” –
products that can help smokers endure
stretches of time (such as work or airplane
rides) where smoking is not permitted.
Zeller warned that providing and
promoting such a bridge might actually
make it harder for certain individuals to
quit smoking cigarettes.
Geoffrey Ferris Wayne, of the Harvard
School of Public Health, and Mitch Zeller
both discussed the role that harm
reduction products play in tobacco
industry strategy.  Wayne spoke of three
relatively new tactics being embraced by
the industry – U.S. companies making
strategic acquisitions of international
companies; brand proliferation (there are
now over 2,000 different tobacco
products on the market in the United
smokers switched to lower yield
cigarettes out of concern for their health
in the belief that these cigarettes were
less risky or were a step toward quitting,
when in fact the marketing and
promotion of reduced yield cigarettes
may actually have delayed genuine
attempts to quit.  Zeller suggested that
the light cigarette experience should
make us very cautious of tobacco
industry attempts to introduce
innovative products.  To highlight this
concept, Zeller discussed a recent survey
in which individuals were asked about
Mitch Zeller
Pinney Associates
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States); and cross promotion of brands,
e.g., Camel Snus.  Zeller took suspicion
of the industry one step farther by
suggesting that tobacco companies are
promoting smokeless tobacco products
not to achieve a market success but to
repair their tarnished image – a public
image that plummeted because of
tobacco litigation successes in the 1990s.
Douglas F. Gansler, Maryland’s
recently elected Attorney General,
introduced the conference’s keynote
speaker, Dr. Cheryl Healton.  Dr.
Healton is the President and CEO of the
American Legacy Foundation, a nonprofit
public health organization created by the
historic Master Settlement Agreement
regarding tobacco.  Dr. Healton began
her spirited comments by noting that
tobacco control advocates are “jaded”
after having been misled by the tobacco
industry “for decades” and are, therefore,
automatically suspicious of reduced harm
products.  From her perspective, reduced
harm products are going to make it
harder for nicotine addicts to quit
smoking because tobacco industry
marketing strategies will convince
smokers that reduced harm products are a
safer alternative.  Because there is no
evidence that such products eliminate the
risks related to smoking, Dr. Healton
argues that tobacco control advocates
should not embrace these products but
rather advocate for complete tobacco
abstinence.
Dr. Mark Shields of Georgetown
University discussed the
science behind risk
reduction products and
the difficulty in
determining whether
reduced exposure to
tobacco actually leads to
a reduction of the health
risks posed by tobacco.
Because public health
advocates cannot wait
for long term
epidemiological studies
to be completed on
these products and
because of the number
of factors that contribute
to an individual’s
tobacco-related risk
level, Dr. Shields
concluded that any discussion of reduced
harm products will involve some
uncertainty.  Shields asked conference
attendees to think about how much
uncertainty they would be willing to
accept as they made policy in this area
and, as a corollary, how much risk
reduction is enough?
Two speakers, William Godshall of
Smokefree Pennsylvania and David
Sweanor of the University of Ottawa,
made strong cases for accepting a
decreased, but not complete, risk
reduction by embracing the use of
smokeless tobacco products.  They both
stressed the importance of accepting the
grim realities of tobacco use and making
the rational decision to promote reduced
harm products for the statistically-
established number of smokers who
cannot or will not quit.  Both speakers
stressed that the tobacco control
community, in its zealousness to fight the
ravages of tobacco, may be abandoning
Micah Berman
Tobacco Public Policy Center
this group although substantial evidence
exists that reduced harm products do
offer smokers with a lower risk
alternative to smoking.  Sweanor argued
that an “abstinence only” approach is
“inconsistent with what science tells us
about addiction and self-medication.”
Sweanor is further convinced that, if
governments step in and regulate the
smokeless tobacco market, the industry
will produce innovative and safer
products.  The idea that regulation
shapes the market can be seen, Sweanor
points out, in the pharmaceutical,
automotive, and food industries.
Several speakers provided legal and
legislative updates in the area of reduced
harm products.  Micah Berman,
Executive Director of the Tobacco
Public Policy Center in Ohio, suggested
a legal response to cigarette companies
“going smokeless,” i.e., expanding and
promoting their smokeless tobacco
product lines.  In Berman’s view,
although smokeless products may have a
role in reducing the harm of tobacco, the
motives and methods behind the
industry’s entrance into the market does
matter because “their goal is not harm
reduction.”  In fact, argues Berman, the
industry undercuts its own claims of harm
reduction by marketing to young people,
people who have never smoked, and
former smokers; by promoting the
products as accompaniments, not
(l-r) Dean Karen Rothenberg, Maryland
Attorney General Douglas Gansler,
Professor Kathleen Dachille
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replacements, to combustible tobacco;
and by not making these products as safe
as possible.  Berman suggested that
addressing these issues should become
policy goals for the tobacco control
community.
Professor Richard Daynard from
Northeastern University School of Law
provided an update on tobacco litigation.
He told the conference that “tobacco
litigation matters” because it tarnishes the
image of tobacco companies, forces the
industry to raise the price of its products,
and results in better settlements for
plaintiffs.  Both Daynard and Berman
discussed a new dilemma that tobacco
companies now face in promoting safer
products.  In a number of tobacco cases,
plaintiffs lost because they could not
show that there was a “feasible alternative
design” to the cigarette.  Companies
presenting reduced harm products may be
forfeiting this defense by selling a product
that is, in fact, a feasible alternative.  Both
speakers suggested that the tobacco
control community investigate this
conundrum as a possible opening for
litigation against the industry.
To round out a day of provocative
discussion, Chris Bostic, a clinical
instructor for the law school’s Tobacco
Control Clinic and Legal Counsel to the
Framework Convention Alliance, and Dr.
Vera Luiza da Costa e Silva, former
director of the Tobacco Free Initiative at
the World Health Organization, gave
attendees an update on the
implementation of the WHO’s landmark
Framework Convention for Tobacco
Control and international perspectives on
reduced exposure products.
Many speakers and attendees agreed
that the conference was invaluable in
bringing forward the two sides of this
issue and a good base upon which to form
a coherent set of future policy
recommendations.  The burning in the
camel’s ear is likely to become a deafening
roar in the years to come.
CHRIS BOSTIC JOINS TOBACCO CENTER
This year, the Tobacco ControlCenter added internationaltobacco control efforts to its
scope of work.  To foster this new
endeavor, the Center hired Chris Bostic,
legal counsel to the international
Framework Convention Alliance for
Tobacco Control (FCA). Bostic joined the
Tobacco Center in the fall of 2006 as a
consultant and in 2007 became a clinical
instructor, working with students in the
tobacco control clinic.  Bostic’s primary role
within the Center is to serve as a liaison
with the global tobacco control community
and to identify and attract global clients to
the Center’s Tobacco Control Clinic.
Bostic brings years of domestic and
international experience in the world of
tobacco control to his work at the Center.
Bostic gained his first exposure to tobacco
control as a student attorney at the
Campaign for Tobacco-Free Kids while
attending American University Washington
College of Law in Washington, D.C.  He
then went on to work at the American
Lung Association as a Program Manager.
As a clinical instructor in the tobacco
control clinic, Bostic has been working
with students to identify potential legal
conflicts for countries that arise when
they attempt to implement measures to
encourage alternatives to tobacco crops
and also carry out trade agreement
obligations, particularly obligations related
to membership in the World Trade
Organization.  This project stems from
the ongoing discussion on the
international level regarding tensions
between trade and tobacco control.
According to Bostic, this discussion has
focused almost entirely on demand-
reduction strategies, i.e., warning labels
on cigarette packages, advertising and
marketing, etc.  The students’ research is
designed to assist policy makers on how
to avoid being dragged into a trade court
for tobacco growing policies.
When Bostic is not working with the
Center, he is either consulting for the
FCA or the Tobacco Control Legal
Consortium.  The FCA is a coalition of
over 200 organizations and networks from
more than 90 countries working to
support the Framework Convention on
Tobacco Control, the landmark
international tobacco control treaty that
was negotiated by the 192 member states
of the World Health Organization
(WHO).  Working on similar issues at a
national level, the Tobacco Control Legal
Consortium is a national network
supporting tobacco control policy change
by giving advocates better access to legal
expertise.
In February, Bostic took two
University of Maryland law school
students to Brasilia, Brazil for the first
meeting of the Framework Convention
on Tobacco Control’s Ad Hoc Study
Group on Alternative Crop (see article, p.
8.)
Also, in keeping with his life of globe-
trotting advocacy, Bostic will attend the
second session of the Conference of the
Parties to the WHO Framework
Convention on Tobacco Control in
Bangkok, Thailand in June.
Chris Bostic
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Gemma Vestal (‘02) doesn’t spendmuch time in the Genevaheadquarters of the World
Health Organization (WHO) where she
serves as  Legal Officer and Scientist for the
WHO’s Tobacco Free Initiative (TFI).  In
2006, Vestal’s position took her to such
places as France, Turkey, Canada, Japan,
Germany, Norway, and back here to the
United States to focus international
attention, resources and action on the
global tobacco epidemic.  Established in
July 1998, the TFI’s objective is to reduce
the global burden of disease and death
caused by tobacco, thereby protecting
present and future generations from the
devastating health, social, environmental,
and economic consequences of tobacco
consumption and exposure to tobacco
smoke. To accomplish its mission, the TFI
provides global policy leadership,
encourages mobilization at all levels of
society, and promotes the WHO
Framework Convention on Tobacco
Control by encouraging countries to adhere
ALUM WORKING AT W.H.O. ON
INTERNATIONAL TOBACCO CONTROL
In February 2007, Chris Bostic, theTobacco Control Center’s newclinical instructor, took two law
school students, Lauren Willis and Alva
Wright, to Brasilia for the first meeting of
the Ad Hoc Study Group on Alternative
Crops.  This study group was convened as
part of the World Health Organization
Framework Convention on Tobacco
Control (FCTC). Article 17 of the FCTC
mandates that parties to the convention
“promote, as appropriate, economically
viable alternatives for tobacco workers,
growers and, as the case may be, individual
sellers.”  Policy makers in this area believe
that tobacco growers should substitute
TOBACCO CLINIC STUDENTS ATTEND
CONFERENCE IN BRASILIA
alternative crops for tobacco or engage in
alternative livelihoods not only because of
market forces (basic economic principles
dictate that a decrease in demand for
tobacco products will result in a drop in
price) but also because of the negative health
and social issues associated with the
cultivation of tobacco.  (As a side note, the
most successful transition to alternative crops
worldwide has taken place in Maryland,
where there has been an 80% reduction in
the amount of tobacco grown.)
At an open meeting on the first day of
the study group’s gathering in Brasilia, the
Maryland contingent represented the
to its principles and supporting them in
their efforts to implement tobacco control
measures based on its provisions.  In the last
year, Vestal met several times with key
stakeholders to develop guidelines for the
implementation of Articles 9 and 10 of the
FCTC relating to the contents of tobacco
products and disclosure of those contents.
She has also worked with experts to discuss
the best ways to translate data gathered
under the FCTC into meaningful
regulatory tools.  Vestal calls her job
“incredibly challenging and rewarding.”
Vestal earned her J.D. from the law
school in 2002.  While she was here, she
served as Associate Editor of the Journal of
Health Care Law & Policy and was a Board
Member of the Student Health Law
Organization.  Vestal also has an MPH from
the Johns Hopkins Bloomberg School of
Public Health, an MBA from the University
of Baltimore, and a BS in Nursing.  Vestal
hasn’t always worked at the highest level of
international policy making – she also
worked on the ground as a flight nurse in
California for two years.  Vestal is an
inspiration for all health law students who
work as interns and law clerks in health law
organizations.  What Vestal calls a
“serendipitous” week-long legal internship
with the World Health Organization in July
2002 led to her current position.  The
conference was held at the United Nations
in New York and Vestal’s participation in
the conference was arranged by L&HCP
faculty member, Allyn Taylor.
Cont. on page 20
Cont. on page 20
Gemma Vestal
(l-r) Lauren Willis,
Alva Wright, Chris Bostic
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U.S. DEPARTMENT OF JUSTICE
OPENS INVESTIGATION INTO
BALTIMORE’S ZONING
STANDARDS AT URGING OF LAW
SCHOOL’S DRUG POLICY CLINIC
FACULTY AT THE FOREFRONT OF HEALTH POLICY
There are 58,000 citizens inBaltimore who need drugtreatment every year.  But,
according to Professor Ellen Weber and
her Drug Policy Clinic students,
Baltimore’s discriminatory
zoning standards prevent those
residents from getting the
appropriate community-based
care that they need.  And
they’ve gotten an important
watchdog to listen to their
allegations.  Based on a
complaint filed by the students
with the Disability Rights
Section of the Civil Rights
Division of the United States
Department of Justice (DOJ),
the Assistant Attorney General
for Civil Rights has recently
agreed to open an investigation
of the clinic’s complaint that Baltimore
City’s zoning standards for residential drug
treatment discriminate against individuals
with histories of drug dependence.
Drug treatment programs, unlike any
other outpatient or residential health care
services, are required to get community
approval and secure passage of zoning
legislation to open a facility or expand
existing services in any location in the
city.  The zoning process, known as the
conditional use ordinance, dates back to
the early 1960s.  It was created and
incorporated into the City’s Zoning and
Health Codes for the explicit purpose of
permitting communities to exclude drug
treatment programs because of the clients
who would be served.  Currently, the
City Council and other city officials
perpetuate this discriminatory standard by
refusing to introduce or support a
treatment program’s zoning legislation if
community associations in the area of the
proposed facility oppose the siting of the
program in their neighborhood.
Community associations frequently refuse
to provide their approval based on
negative stereotypes stemming from an
unfounded fear of individuals who
require alcohol or drug treatment.   In
addition to the community approval
requirement, the conditional use
ordinance process also requires those
attempting to site treatment programs to
participate in two separate public hearings
and expend significant resources to
navigate the political process.  These
time-consuming and cost-prohibitive
efforts are not required of
other similarly-situated
health care providers.
These combined
requirements have resulted
in the denial of zoning
permits to drug and alcohol
treatment programs –
including programs that have
served the City’s residents
for many years with
exemplary records.  The
students’ complaint
documents the zoning
process, its history and
current use, and individual
cases of intentional discrimination.
Professor Ellen Weber, faculty member
since 2002 and former Senior Vice
President for the Legal Action Center,
created the Law School’s Drug Policy
and Public Health Strategies Clinic to
address practices that inhibit the
expansion of drug treatment in
communities and the criminal justice
system and discriminate against individuals
with histories of drug dependence.  To
address the addiction issues that drive
much of the crime in certain Baltimore
neighborhoods, Weber and her students
use legal and policy advocacy strategies to
both force and encourage the City to
provide better health care services.
This recent success with the DOJ
investigation comes on the heels of the
enactment of zoning legislation by the
Baltimore City Council that invalidated
discriminatory zoning standards that have
banned outpatient drug treatment
programs from many communities.  The
Drug Policy Clinic had worked for four
years with its client, a coalition of the
City’s drug treatment providers, and other
advocates in the community to persuade
the City to enact this legislation.  The
DOJ investigation is expected to resolve
the remaining zoning barriers to the
expansion of treatment services.
In addition to her work at the law
school, Professor Weber is part of an
interdisciplinary team of University of
Maryland faculty examining substance
abuse issues within the professions.  She
is also participating on a Health Care
Advisory Workgroup convened by the
Maryland Departments of Health and
Mental Hygiene and Human Resources
that is identifying options to improve the
health care delivery system for Baltimore
children in foster care.
L&HCP FACULTY PRESENT
PAPER ON ALTERNATIVES TO
QIOS FOR MEDICARE
BENEFICIARY COMPLAINTS
John Q., the son of a 72 year old nursing
home resident, believes that his father,
Robert, has not been getting adequate care
at the nursing home. Robert has had several
decubitus ulcers. Who should John contact to
complain about Robert’s care?
Although the nursing homeombudsman or the state surveyand licensing agency would be
obvious choices, Medicare beneficiaries
concerned about the quality of health
care they receive are instructed to contact
their local QIO – Quality Improvement
Organization – to lodge a  complaint. QIOs
are the federal government’s primary tool
for assuring that services provided to
Medicare beneficiaries are medically
necessary, of a quality that meets
professionally recognized standards of health
care, and provided in an appropriate setting.
The government spends approximately
$400 million a year on the QIO program,
which includes 41 contractors who cover
all 50 States and Washington D.C., Puerto
Rico, and the Virgin Islands.
Cont. on page 10
Ellen Weber
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Faculty at the Forefront
Cont. from p. 9
QIOs that receive a complaint from a
beneficiary are required, at a minimum, to
notify a complainant of the results of a
review and to disclose their determinations as
to whether the quality of the services that
the recipient received met professionally
recognized standards of health care.
Despite being funded to provide this
service, there have been numerous criticisms
levied at QIOs in carrying out the complaint
review process. These criticisms have been
voiced through reports prepared by the
Office of the Inspector General (OIG) and
the Institute of Medicine (IoM) which state
that QIOs: 1) receive very few complaints
because beneficiaries are generally unaware of
the complaint process; 2) do not provide
complainants with meaningful, substantive
responses to their complaints and take too
long to respond; 3) resolve very few
complaints and take limited action in
response to substantiated complaints.  In
2006, the IoM, as a result of its findings,
recommended removing the function of
performing quality of care investigations from
the QIOs and allowing other entities to
perform this work while QIOs continue to
focus more specifically on assisting health
care providers in quality improvement.
In response to the IoM recommendation,
and with support from The Commonwealth
Fund, the Center for Medicare Advocacy
commissioned two papers, one by Professor
Diane Hoffmann and L&HCP Coordinator
Virginia Rowthorn, to explore possible
alternative entities that might carry out the
complaint process, and a second by Dr. Peter
Hollmann, to examine the attributes of an
ideal complaint process. In January of this year,
the Center staff, led by Judith Stein and
Alfred Chiplin, convened a working
conference, at which Hoffmann, Rowthorn
and Hollmann presented their papers. The
purpose of the conference was to design a
“model” complaint process for Medicare
beneficiaries.
The conference provided a forum for key
stakeholders to discuss concerns and develop a
blueprint for change.  Forty-two invited
experts from a variety of backgrounds
attended the conference. They included Barry
Straube, Chief Medical Officer and Director
of the Office of Clinical Standards and Quality
at the Centers for Medicare & Medicaid
Services; David Schulke, Executive Vice
President of the American Health Quality
Association; Lisa Robin, Vice President of
Government Relations, Policy, and
Education for the Federation of State
Medical Boards; Julie Taitsman, Special
Counsel for Health and Science for the U.S.
Senate Committee on Finance; and, Eleanor
Kinney, Co-Director of the Hall Center for
Law and Health at the Indiana University
School of Law.
Hoffmann and Rowthorn’s paper, which
provided the backdrop for the discussion of
a model complaint process, reviews the
literature on the performance of QIOs in
responding to Medicare beneficiary
complaints, sets forth criteria for evaluating a
Medicare beneficiary complaint process, and
uses the criteria to assess how existing entities
that already conduct similar work, e.g., state
medical boards and state survey agencies,
would fare as possible alternatives to QIOs in
responding to Medicare beneficiary
complaints. Hoffmann and Rowthorn
concluded that, while these alternative
entities have considerable experience
responding to complaints from consumers
and patients about health care quality and
fare better on a number of evaluative criteria
than QIOs, they also have weaknesses that
would make it difficult to rely on them in
their current form to undertake this task.
Chief among these weaknesses is the
variation in these entities from state to state,
the limited scope of authority of the state
survey agencies (i.e., to institutional providers)
and state medical boards (to physicians), and
the limited oversight the federal government
has over state medical boards.  A copy of
Hoffmann and Rowthorn’s paper, along with
the recommendations of the conference
working group, is available at http://
www.medicareadvocacy.org/
projects_QIOConference.htm.
L&HCP DIRECTOR ADDRESSES
EPIDEMIOLOGISTS ON LIABILITY
RELATED TO HEALTHCARE
ACQUIRED INFECTIONS
According to the U.S. Centers forDisease Control and Prevention,health care acquired (or
nosocomial) infections cause 90,000 deaths
per year in the United States and result in
an estimated eight million excess hospital
days and more than $5 billion in excess
healthcare costs each year.  The microbe
that causes the majority of serious
nosocomial infections is methicillin-
resistant staphylococcus aureus or MRSA.
MRSA lurks on the body of one in every
20 patients entering the hospital1 and
research has shown that of those patients
who have it on their bodies at admission,
up to one in five develops an infection.2
To address this problem, some
hospitals are taking steps to identify
patients carrying MRSA when they are
admitted to the hospital or ICU.  Patients
who are identified as having the infection
are isolated and treated appropriately.
This strategy, called surveillance screening
or universal surveillance, has proven
extremely successful in Denmark and the
Netherlands, both of which have brought
the level of MRSA infection in hospitals
down to almost nonexistent.3 At Boston’s
Brigham and Women’s Hospital, high-
compliance screening for MRSA in adult
ICUs led to dramatic decreases in MRSA
bloodstream infections throughout the
hospital.
While some hospitals are implementing
surveillance screening, others are nervous
about the potential legal liability associated
with such screening programs. The
information generated by such surveillance
is one issue that makes some hospitals
nervous. In addition, a number of states
are passing bills requiring mandatory
reporting of nosocomial infections. This
data may ultimately be used to compare
rates of nosocomial  infections across all
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UMD LAW STUDENT  VISITS
KENYA WITH THE BUSINESS
WOMEN’S INITIATIVE AGAINST
HIV/AIDS
In 2006, because of her expertise onwomen and AIDS issues bothnationally and around the world,
Karen Rothenberg, Dean of the
University of Maryland Law School, was
asked to serve as academic advisor to the
Business Women’s Initiative Against HIV/
AIDS (BWI).  BWI, the brainchild of
Mary Robinson, former United Nations
High Commissioner for Human Rights and
President of Ireland, and Mary Ann
Leeper, President and Chief Operations
Officer of the Female Health Company, is
an alliance of business leaders and
nongovernmental organizations (NGOs)
created to bring innovative and holistic
approaches to help empower women with
the education and interventions to protect
themselves from HIV/AIDS.
In November, Dean Rothenberg
invited Andrea Vaughn, a joint JD/MPH
student, to represent her during BWI’s first
fact-finding mission to Africa.  Andrea
joined a group of prominent BWI
members on this landmark visit which
took them to Nairobi and Kisimu, Kenya.
BWI’s goal is to create links between
business women in the United States and
Europe with women leaders in Africa who
have demonstrated their expertise in
working within their communities.  One
of BWI’s primary goals is to promote the
availability and use of the female condom
– the only available method to prevent
HIV/AIDS that is under a woman’s
control.  BWI has voiced its concern that,
despite the proven effectiveness of the
female condom, bureaucracy, shortage of
funds, and lack of commitment to women
are thwarting the broad distribution of
these products to those most in need.
BWI also advocates further research and
development of microbicides as a critical
preventive technology that will greatly
empower women in the coming years.
FACULTY & STUDENTS IN AFRICA
The group met with members of the
Kenyan parliament, government officials,
representatives of local and international
NGOs, business leaders and local attorneys.
Andrea and the rest of the group also had
the opportunity to visit several nonprofit
organizations including the Girls
Empowerment Programme, Girl Guides
Project, Leo Toto (a nutritional care
program for children infected by HIV),
Women Fighting AIDS in Kenya
(WOFAK), and the Federation of Kenyan
Women Lawyers (called FIDA).  FIDA is
one of the only groups in Kenya that
provides legal services to women – mainly
handling cases relating to alimony,
succession, violence, genital mutilation, and
property claims.
Andrea, who has traveled overseas
extensively and served as a Peace Corps
volunteer in Ecuador, was deeply moved by
her experience in Africa.  One of the
greatest lasting impressions she came away
with was the enormous dedication of the
women working on the ground to improve
the lives of women and children in Kenya –
“I believe more than ever that we don’t
have the answers – these women have the
answers, or as close as there are to answers,
and we need to find a way to support their
efforts.”
Andrea Vaughn ‘07 (center)
ROTHENBERG  ADDRESSES
UNIVERSITY OF CAPETOWN LAW
SCHOOL ON THE DEADLY
INTERSECTION OF DOMESTIC
VIOLENCE AND HIV/AIDS
In March, Dean Karen Rothenbergvisited Capetown, South Africa, toformalize a faculty/student exchange
program between our law school and the
University of Capetown Law School.
While there, she addressed a group of
law school faculty and students as well as
representatives of local legal aid
organizations.  In her talk entitled “The
Intersection of Domestic Violence and
HIV/AIDS:  Learning from the Past,
Lessons for the Future,” Rothenberg
Cont. on page 19
told the story of the law school’s early
encounters with the now well-
documented intersection of these two
public health crises.  In 1987, two of the
law school clinic’s female clients were
assaulted when their partners learned of
their HIV status.  This prompted
Rothenberg to study the issue of partner
notification in greater depth and plan the
Karen Rothenberg with University
of Maryland law students
Jessica George, Brigid Ryan, and
Melissa Hill in Capetown*
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FOCUS ON EXTERNSHIPS . . . BRIAN KEHOE
OFFICE OF LEGISLATION/FDA
The health law externship programat the University of MarylandSchool of Law allows students the
opportunity to gain valuable experience
in a variety of government and non-profit
settings.  During the Spring semester, I
spent two days a week in the Office of
Legislation (OL) at the U.S. Food and
Drug Administration (FDA).
The OL serves as the liaison between
Congress and the Agency and has
provided me with a window into the real-
world workings of the U.S. regulatory
system. The OL staff spend the majority of
their time on two broad tasks. First, OL
responds to all of the congressional
inquiries received by the Agency. These
inquiries vary substantially and might deal
with general policies or be specific to an
individual constituent. The OL also takes
the lead when the FDA testifies before
Congress. This involves drafting testimony
and reviewing pending legislation, and
requires an understanding of the issues and
current political climate.
The office is made up of three teams
which specialize respectively on food,
drugs, and biological products. Team
members develop specific expertise but
there is extensive collaboration. For
example, each Congressional hearing is
assigned to one team member. While a
hearing will focus on one issue, the FDA
witness must be prepared to answer a
range of questions from members of
Congress. Team members work together
to brief the witness on the hot issues
likely to arise during the hearing.
I have been working on the drugs
team, which has allowed me to get
involved in a wide range of activities.
Initially, I was given responsibility for
responding to Congressional inquiries
into drug importation. Drug importation
has been a hot issue in the last few years
due to the high prices of U.S. brand
name drugs compared to their foreign
counterparts. Many Americans have
sought to purchase cheaper drugs
through online pharmacies that offer
foreign drugs at lower prices. Such
personal drug importation violates federal
law. Foreign drugs are produced
outside of the U.S. regulatory system
and without assurances that these
drugs are safe and effective. Although
there is a real potential that these
foreign drugs might be counterfeit
with harmful ingredients, there are
also more potential subtle dangers.
Drugs are manufactured under
complicated specifications designed to
ensure standardization. Foreign drugs
might be more or less potent and
might not enter the bloodstream at
the same rate as those manufactured in
the U.S.
While the FDA does not have the
resources to inspect a large percentage
of incoming packages, the FDA does
intercept a portion of imported drugs.
Many individuals contact their
Congressional representatives who, in
turn, request information from the
FDA about the status of their
packages. When I received these
requests, I would contact the field
inspectors to learn the details of the
detention. I then would contact the
Congressional staff to explain the
FDA’s role in enforcing federal law
and the details of the specific
detention. There were also instances
where, based on the information I
received, FDA decided to release the
imported drug. This happened, for
example, when there was not a U.S.
version of the foreign drug and the
drug was required to treat a serious
condition.
I also had the opportunity to help
in the preparation for and attend
several congressional hearings.  In
March, the Senate Committee on
Health, Education, Labor, and
Pensions held a hearing to consider
reauthorizing the Prescription Drug
User Fee Act (PDUFA). PDUFA was
originally passed in 1992 and provides
increased funding for the FDA
through industry fees. I drafted the
Commissioner’s written testimony
using previous PDUFA testimony,
Federal Register documents, and
internal materials.  The written testimony I
helped to prepare for the Commissioner will
appear in the Federal Register.  I joined
several briefing sessions where senior FDA
staff members and the Commissioner
discussed areas of potential Congressional
concern. After attending the hearing, I
prepared a hearing report detailing the views
of the different witnesses and the concerns
that were raised.
My externship experience at the FDA has
been a valuable aspect of my legal
education. I encourage other students to
take advantage of the varied opportunities
that are available through the Law & Health
Care Program.
Brian, who graduated this spring with the
Health Law Certificate, also interned at
Greater Boston Legal Services,
MedImmune, and the American Pain
Foundation during his three years at the
law school.  Brian was recently chosen as a
Presidential Management Fellow, a two
year paid government fellowship sponsored
by the Office of Personnel Management.
Although Brian could have chosen positions
in other branches of the government, he has
decided to remain at the FDA’s Office of
Legislation for his fellowship.
Brian Kehoe
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L&HCP FACULTY NOTES . . .
FROM MAY 2006 TO MAY 2007
Richard Boldt
ARTICLES:
“Juristocracy in the Trenches: Problem-
Solving Judges and Therapeutic
Jurisprudence in Drug Treatment Courts
and Unified Family Courts,” 65 Maryland
Law Review 82 (2006) (with Jana Singer)
Kathleen Dachille
PRESENTATIONS:
Debate, ”Does Parental Smoking
Constitute Child Abuse? Striking the
Rights Balance,” The National Center for
Adoption Law & Policy, Capital
University School of Law, Columbus,
Ohio (October 6, 2006)
 
“Employment Policies Based on Smoking
Habits,” Making the Business Case for
Smoking Cessation and Tobacco Control,
Wolfe Symposium, Columbus, Ohio
(October 6, 2006)
 “Policy and Legislation to Reduce
Tobacco Use and Tobacco-Related
Disease in Maryland,” Maryland Cancer
Council Annual Meeting, Baltimore,
Maryland (November 15, 2006)
Michael Greenberger
ARTICLES:
“The Alfonse and Gaston of
Governmental Response to National
Public Health Emergencies: Lessons
Learned from Hurricane Katrina for the
Federal Government and the States,” 58
Administrative Law Review  611 (2006)
“False Conflict:  Who’s In Charge of
National Public Health Catastrophes,”  31
Admin. & Reg. L. News 2 (2006)
“Choking Bioshield:  The Department
of Homeland Security’s Stranglehold on
Biodefense Vaccine Development,” 1
Microbe 260 (2006)
 “Preparing Vulnerable Populations for a
Disaster:  Inner-City Emergency
Preparedness – Who Should Take the
Lead?,” 10 DePaul J. Health Care L. 291
(2007)
PRESENTATIONS:
“Community Impacts – Potential System
Breakdowns and Community Response
in the Event of a Pandemic Flu,”
Howard County Pandemic Flu Summit,
Columbia, Maryland (May 16, 2006)
“Public Health: The Next Pandemic,”
Panelist, 30th Annual Health Law
Teachers Conference, University of
Maryland School of Law, Baltimore,
Maryland (June 2, 2006)
“Pandemic Flu and Crisis Management
Planning: How Can Immigrants Be
Involved and Prepared,” Panelist,
Maryland Coalition for Refugees and
Immigrants Conference, Anne Arundel
Community College, Arnold, Maryland
(June 14, 2006)
“Bioshield and Vaccine
Commercialization,” Middle Atlantic
Regional Center of Excellence in
Biodefense and Emerging Infectious
Disease Research (MARCE) Fall
Meeting, University of Virginia School
of Medicine, Charlottesville, Virginia
(October 18, 2006)
“The Public’s Health and the Law in the
21st Century: A Public Health Legal
Preparedness Summit,” Invited
Participant, Center for Disease Control
Planning Meeting, Atlanta, Georgia
(October 20, 2006)
“Using Legal Preparedness to Build
Partnerships with the Private Sector,”
Panelist, American Public Health
Association Partnership Breakfast, Boston,
Massachusetts (November 6, 2006)
“Is Anyone or Everyone in Charge?
Responding to Regional Catastrophic
Public Health Events,” Organizer and
Facilitator, Middle-Atlantic Regional
Center of Excellence for Biodefense and
Emerging Infectious Diseases Research
(MARCE) Emergency Preparedness
Conference, Uniformed Services
University of the Health Sciences,
Bethesda, Maryland (February 27, 2007)
Deborah Hellman
ARTICLE:
“Physicians as Researchers: Difficulties
with the ‘Similarity Position’,” American
Journal of Bioethics, July/Aug. 2006, at 57
(with D. Wasserman & R.S. Wachbroit)
Diane Hoffmann
ARTICLES:
“The Legal Column: Choosing
Paternalism?,” Lahey Clinic Medical Ethics,
Vol. 13, Issue 2, p. 4 (Spring 2006)
“Who decides whether a patient lives or
dies?,” Trial, Vol. 42, No. 10, pp. 30-37,
(October 2006) (with Jack Schwartz)
“A Statewide Survey Identifying Perceived
Barriers to Hospice Use in Nursing
Homes,” Journal of Hospice and Palliative
Nursing, Vol. 8, No. 6, pages 1-10
(November/December 2006) (with Anita
Tarzian)
 “The Role and Legal Status of Health
Care Ethics Committees in the U.S.,” in
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LEGAL PERSPECTIVES IN BIOETHICS: ANNALS
OF BIOETHICS SERIES (Sandra Johnson &
Ana Iltis, eds.) (book chapter) (with Anita
Tarzian)
“Legal Issues in the Treatment of Pain,”
in COMPLICATIONS IN REGIONAL ANESTHESIA
& PAIN MEDICINE, Joseph M. Neal and
James P. Rothwell (eds.) (Saunders
Elsevier, 2007) (book chapter)
“Can State Medical Boards Adequately
Respond to Reports that Physicians are
Inappropriately Prescribing Opioids?,” 81
Clinical Pharmacology & Therapeutics 799
(2007)
PRESENTATIONS:
“Resuscitation at the End of Life,”
Hospice Network of Maryland Annual
Meeting, Baltimore, Maryland (November
1, 2006)
“The Medicare Beneficiary Complaint
Process: QIO’s and Possible
Alternatives,” keynote speaker, Center
for Medicare Advocacy
Conference, Washington, D.C. (January
19, 2007)
 “Futility & Medically Inappropriate Care:
Policy Approaches to Limiting Health
Care at the Margins,” Conference
sponsored by the Maryland Healthcare
Ethics Network on “Money and
Medicine: Bedside Ethics of the Medical
Marketplace,” Greater Baltimore Medical
Center, Baltimore, Maryland (January 30,
2007)
“Legal Issues Associated with Nosocomial
Infections,” Patient Safety Symposium,
University of Maryland Medical System,
Baltimore, Maryland (January 30, 2007)
“Legal Obstacles to the Treatment of
Chronic Pain,” ABA Mid-Winter
Meeting, Section of Labor and
Employment Law, Workers’
Compensation Committee, Naples,
Florida (March 2, 2007)
“Judging Genes: Judicial Response to the
Second Generation of Genetic Tests,”
Program in Genetics and Genome
Medicine Seminar Series Presentation,
University of Maryland School of
Medicine, Baltimore, Maryland (March
14, 2007)
“Law and Order: The Changing Legal
Landscape Around Healthcare Associated
Infections,” The Society for Healthcare
Epidemiology of America, Baltimore,
Maryland (April 15, 2007)
“Maternal Immunization: Liability and
Other Legal Issues,” The Tenth Annual
Conference on Vaccine Research,
Baltimore, Maryland (May 1, 2007)
APPOINTMENTS:
CDC Advisory Committee on
Immunization Practices (ACIP) workgroup
on vaccines during pregnancy and
breastfeeding.
Karen Rothenberg
ARTICLES:
 “National Institutes of Health State-of-
the-Science Conference Statement on
Cesarean Delivery on Maternal Request,”
107 Obstetrics and Gynecology 1386 (2006)
“The Scarlet Gene: Behavioral Genetics,
Criminal Law, and Racial and Ethnic
Stigma,” 69 Law and Contemporary Problems
343  (2006) (with Alice Wang)
PRESENTATIONS:
“Judging Genes: Judicial Response to the
Second Generation of Genetic Tests,”
Southeastern Association of Law Schools
Annual Meeting, Palm Beach, Florida
(July 17, 2006)
“The Intersection of Domestic Violence
& HIV/AIDS,” Faculty Presentation,
University of Cape Town, South Africa
(March 20, 2007)
OTHER ACTIVITIES/
APPOINTMENTS/AWARDS
Maryland Stem Cell Commission (2006-
2008)
Board Member, Kaiser Foundation Health
Plan of the Mid-Atlantic States, Inc.
(2006-present)
Congressional Testimony, “Protecting
Workers from Genetic Discrimination,”
Committee on Education and Labor at
the Subcommittee on Health,
Employment, Labor and Pensions
(HELP), Washington, D.C. (January 30,
2007)
Lawrence Sung
ARTICLES:
“License to Sue? The Availability of
Declaratory Judgment Actions to Patent
Licensees After MedImmune, Inc. v.
Genentech, Inc.,” Intellectual Property
Today (January 2007)
PRESENTATIONS:
 “Can I Get There From Here?,” 56th
Annual Meeting of the American Society
of Human Genetics, New Orleans,
Louisiana (October 10, 2006)
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OTHER ACTIVITIES/
APPOINTMENTS/AWARDS
Interview, “High Court Backs
MedImmune,” Baltimore Sun (January 10,
2007)
Allyn Taylor*
ARTICLES:
“Global Health Law,” ENCYCLOPEDIA OF
PUBLIC HEALTH (Elsevier Science, 2006)
“A Guide to the Domestic
Implementation of the WHO Framework
Convention on Tobacco Control,”
Framework Convention Alliance (2006)
PRESENTATIONS:
“The WHO Framework Convention on
Tobacco Control and Global Health
Lawmaking,” Georgetown University
Law Center, Washington, D.C. (October
24, 2006)
“Health Security, Human Security and
Human Rights” International Health Law
and Policy 2006: Health, Ethics, Human
Rights and International Regimes
Conference, organized by the National
University of Taiwan College of Law
Asian Center for the WTO and
International Health Law and Policy and
the Taiwan Department of Health,
Taipei, Taiwan (December 4, 2006)
“SARS: What Really Happened and
Why International Health Law and Policy
Will Never Be the Same,” with Dr. Jamie
Maguire, University of Maryland School
of Medicine Department of
Epidemiology Seminar Series, Baltimore,
Maryland (December 14, 2006)
OTHER ACTIVITIES/
APPOINTMENTS/AWARDS
Committee Member, Gates Global
Health and Foreign Policy Initiative
Appointments Committee, The Johns
Hopkins University Paul H. Nitze School
of Advanced International Studies,
Washington, D.C. (September 2006 –
Present)
Invitation, “Establish a UNESCO
Bioethics Collaborating Centre,
UNESCO Chair in Bioethics (2007)
Robin Wilson**
ARTICLE:
“The Challenge of Regulating Known
Unknowns,” 34 Journal of Law, Medicine &
Ethics 704 (Winter 2006)
PRESENTATIONS:
“Publishing Strategies for Health Law
Teachers,” Moderator and Presenter,
Health Law Teachers Conference,
University of Maryland School of Law,
Baltimore, Maryland (June 1, 2006)
“Nanotechnology: The Challenges of
Regulating Known Unknowns”
American Academy of Nanomedicine,
Second Annual Conference, National
Academy of Science, Washington, D.C.
(September 11, 2006)
 “Medicare: Where’s The Common
Sense? A Response to Medicare Meets
Mephistopheles by David A. Hyman,”
Cato Institute, Washington, D.C.
(September 21, 2006)
 “Keynote: Consent: The Law and
Hysterectomy,” HERS Foundation,
Twenty-Fifth Annual Hysterectomy
Conference, Nashville, Tennessee
(October 28, 2006)
“Matters of Conscience:  Evaluating the
Duty to Dispense Emergency
Contraceptives,” University of Virginia
School of Medicine, Medical Center
Hour, Charlottesville, Virginia (October
18, 2006) 
OTHER ACTIVITIES/
APPOINTMENTS/AWARDS
Guest, Book Notes on C-Span,
“Medicare Meets Mephistopheles by
David A. Hyman discussion” (October 22,
2006)
*During the 2006-2007 academic year,
Allyn Taylor had a joint appointment at
the University of Maryland Schools of
Medicine and Law.  Next year, she will
be joining the faculty at Georgetown
University School of Law as a Visiting
Professor.
**During the 2006-2007 academic year,
Robin Wilson was visiting at Washington
& Lee University School of Law.  Next
year she will be joining the faculty there.
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States signed the treaty but President
Bush has not yet sent the treaty to the
U.S. Senate for ratification.  The White
House has said that it is continuing to
study the treaty.  Senate ratification
would permit the U.S. to participate as a
full party when the treaty’s governing
body, called the Conference of the
Parties, meets to discuss
implementation, funding and
enforcement of the FCTC.
The early success of the treaty
reflects strong support from the
developing world. Some have
attributed this to the increasingly
“inequitable distribution of tobacco-
related deaths, 70 percent of which
will occur in developing countries by
2030.”13  Support for the treaty may
have also been a result of an influential
report from the World Bank,
“Curbing the Epidemic,” which
“helped reverse the longstanding
perception that the tobacco industry
was economically too beneficial to
developing countries to allow for
effective health regulation.”14 The
treaty gained widespread support
despite efforts by the tobacco industry
and international tobacco growers to
undermine its passage. Next steps for
implementation include putting in place
the necessary infrastructure in each
country and incorporating the treaty
provisions into national laws.  WHO is
providing guidelines and materials to assist
countries in this effort.
Renewed Efforts at the Federal Level
In 1996, the Food and Drug
Administration (FDA) asserted jurisdiction
over tobacco products under the Food,
Drug, and Cosmetic Act through
proposed regulations designed to regulate
tobacco advertising, promotional
campaigns, labeling and purchasing
restrictions. The tobacco industry sued
Focus on Tobacco Regulation
Cont. from p. 3
the federal government, arguing that the
FDA lacked legal authority to regulate
tobacco products. The Supreme Court
ruled in June 2000 that Congress had not
expressly given the FDA legal authority
to regulate the tobacco industry and that
Congress must specifically enact
legislation to allow the FDA to regulate
tobacco. As a result, all FDA tobacco
regulations were dropped, including the
federal minimum age requirement (18
years old) for tobacco products and
federal rules requiring retailers to check
photo identification.
On February 15, 2007, U.S. Senators
Edward M. Kennedy (D-MA) and John
Cornyn (R-TX) and U.S. Representatives
Henry A. Waxman (D-CA) and Tom
Davis (R-VA) introduced identical,
bipartisan bills (S. 625/H.R. 1108) to grant
the FDA authority to regulate tobacco
products.15  This legislation has been
strongly endorsed by the American
Cancer Society Cancer Action Network,
the American Heart Association, the
American Lung Association, the
Campaign for Tobacco-Free Kids, and
numerous public health, faith and other
organizations around the country.
This legislation would grant the FDA
enormous authority to regulate both
current and new tobacco products and
restrict tobacco product marketing.  The
bills require that the FDA’s 1996 Rule
(referenced above) be republished within
one month and take effect within one
year of enactment of the legislation.
Specifically, these rules:
• Ban all outdoor tobacco advertising
within 1,000 feet of schools and
playgrounds.
• Ban all remaining tobacco brand
sponsorships of sports and
entertainment events.
• Ban free giveaways of any non-
tobacco items with the purchase of a
tobacco product or in exchange for
coupons or proof of purchase.
• Ban free samples and the sale of
cigarettes in packages that contain
fewer than 20 cigarettes.
• Limit any outdoor and all point-of-
sale tobacco advertising to black-and-
white text only.
• Limit advertising in publications with
significant teen readership to black-
and-white text only.
• Restrict vending machines and self-
service displays to adult-only facilities.
• Require retailers to verify age for all
over-the-counter sales and provide for
federal enforcement and penalties
against retailers who sell to minors.
The FDA’s authority in these areas would
not be limited to provisions of the 1996
Rule.  The FDA could take additional
regulatory steps to restrict tobacco
marketing and to prevent tobacco sales to
persons under 18. The legislation would
also:
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requiring tobacco companies to reduce
or remove harmful substances from
cigarettes, including nicotine.18  Both bills
have been referred to Committee – the
Committee on Health, Education, Labor,
and Pensions on the Senate side and the
Committee on Energy and Commerce on
the House side.  Tobacco control
advocates are anxiously awaiting further
Congressional action on a bill that would
dramatically change the legal landscape of
both tobacco use and control.
Endnotes
1 134 F. Supp. 829 (D WD Pa, 2 Aug 1955).
2 Federal Regulation of Tobacco,
available at www.americanheart.org/
presenter.jhtml?identifier=11223.
3 Robert A. Kagan & William P. Nelson,
“The Politics of Tobacco Regulation in the
United States,” available at
http://www.igs.berkeley.edu/
research_programs/hist_papers/tobacco.pdf.
4 Summary of the Attorney Generals Master
Settlement Agreement, Joy Johnson Wilson,
Director, AFI Health Committee, March
1999, for the National Conference of State
Legislatures, available at http://www.ncsl.org/
statefed/tmsasumm.htm.
5 Id.
6 Id.
7 Greg Winter, “State Officials are Faulted on
Anti-Tobacco Programs,” New York Times,
Jan. 11, 2002 (stating that while most states
have used their settlement money to “offset
Medicaid expenses, support children’s
programs or improve education,” the
payments “have also gone to run boot camps
for juvenile offenders in Alabama, build levees
in North Dakota and provide tax cuts in
Illinois and Connecticut”).
• Grant the FDA specific authority to
restrict tobacco marketing.
• Require detailed disclosure of
ingredients, nicotine and harmful
smoke constituents.
• Empower the FDA to establish a
periodically re-evaluated content
standard, and require changes in
tobacco products to meet the
standard.
• Ban all cigarette flavorings other than
menthol, that are a characterizing
flavor of the product.
• Ban the use on labels or in advertising
of terms such as “light,” “mild,” or
“low.”
• Strictly regulate “reduced harm”
products.
• Require bigger, better, health
warnings.
• Establish a Tobacco Products Scientific
Advisory Committee.
• Fund FDA activity through a fee on
tobacco product manufacturers,
allocated by market share.
• Eliminate existing federal preemption
of state laws restricting cigarette
advertising.
• Protect states’ ability to pass other
tobacco control laws.16
A poll commissioned by the Campaign
for Tobacco-Free Kids found that 77% of
registered voters support giving the FDA
the power to regulate tobacco
products.17  The survey of 800 voters,
conducted by Public Opinion Strategies
and the Mellman Group, found that
support for FDA regulation cut across
political and regional lines, and was
backed by strong majorities of smokers
and nonsmokers. The poll also found
strong support for specific regulatory
steps like limiting advertising in
publications with large underage
readerships, regulating relative health
claims about tobacco products, and
8 The 19 states include Arizona, California,
Colorado, Connecticut, Delaware, Hawaii,
Maine, Maryland (effective February 1, 2008),
Massachusetts, Minnesota, Montana (extends
to bars Jan 1, 2009), New Jersey, New
Mexico, New York, Ohio, Rhode Island,
Utah (extends to bars Jan 1, 2009), Vermont,
Washington.   Source:  Michael Strande,
Managing Attorney, Legal Resource Center
for Tobacco Regulation, Litigation and
Advocacy at the University of Maryland
School of Law.  See also State Legislated
Action on Tobacco Issues (SLATI) Overview,
American Lung Association, available at  http:/
/slati.lungusa.org/StateLegislateAction.asp.
9 See SLATI, supra note 8.
10 Id.
11 “An International treaty for tobacco
control,” World Health Organization,
12 August 2003 available at www.who.int/
features/2003/08/en/print.html.
12 Jeff Collin, “Tobacco Politics,” 47
Development 91, 92 (2004).
13 Id.
14 Id.
15 See S. 625 introduced by U.S.
 Senators Edward M. Kennedy (D-MA) and
John Cornyn (R-TX) on February 15, 2007
and H.R. 1108, introduced by U.S.
 Representatives Henry A. Waxman (D-CA)
and Tom Davis (R-VA) on the same day.
16 Id.
17 Poll reported at http://
www.jointogether.org/news/headlines/
inthenews/2007/poll-finds-support-for-
fda.html.
18 Id.
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Center for Tobacco Regulation
Cont. from p. 4
centers–the Secondhand Smoke Technical
Assistance Resource Center (Colorado)
and the Tobacco Public Policy Center
(Ohio).
The TCLC is funded in part by a grant
from the Robert Wood Johnson
Foundation and the American Cancer
Society.  The TCLC’s coordinating office
is located at the William Mitchell College
of Law in St. Paul, Minnesota and is
staffed by Doug Blanke, the Executive
Director, and three attorneys.  Drawing on
the expertise of these legal centers and
others, the TCLC provides assistance to
support the creation of new legal programs
and to help communities and states with
legal needs and technical assistance services
such as legislative drafting, legal research,
legal analysis and strategy, training and
presentations, preparation of friend-of-the-
court briefs, and litigation support.
TCLC also publishes synopses of
tobacco related legislation and court
cases.  In June 2005, TCLC published
“Secondhand Smoke and the Family
Courts:  The Role of Smoke Exposure in
Custody and Visitation Decisions.” The
paper, written by Professor Dachille and
Tobacco Center Research Fellow and
2004 School of Law graduate Kristine
Callahan, has led to many inquiries from
individuals dealing with parental smoking
in custody and visitation cases.
In addition, the TCLC has published
written law synopses on such topics as
secondhand smoke and casinos,1 legal
options for condominium owners
exposed to secondhand smoke,2 the
problems associated with internet
cigarette retailers,3 and an overview of the
ways in which local land use regulations,
such as zoning laws, might be used to
control the location and operation of
tobacco retailers.4
The flavored tobacco products issue is
a topic currently under scrutiny by the
TCLC and the subject of a 2006 law
synopsis entitled “Protecting Maryland
Youth from Candy-Flavored Cigarettes
and Smokeless Tobacco Products” by
Professor Dachille.  In that synopsis,
Dachille urged Maryland to pass a bill
that would prohibit the sale of candy-
flavored cigarettes and smokeless tobacco
products.  She argues that states must
take the initiative to ban candy-flavored
tobacco products, which are disguised as
sweet-flavored treats that serve to entice
and initiate youth
because they
provide an attractive
alternative to the
offensive and strong
taste of the average
tobacco product.
Dachille noted that,
although children
and adolescents are
already prohibited
from purchasing
tobacco products,
the system of age-verification and
enforcement is faulty and thus leaves
plenty of room for young people to fall
between the cracks and purchase these
products illegally.
Tobacco Center:  Non-Legislative Projects
The most common complaint the
Center receives is from individuals living in
multi-unit dwellings – apartments,
condominiums or townhouses – who are
bothered by tobacco smoke drifting into
their unit from an adjacent unit.  For some
complainants, the smokedrift is so pervasive
as to render some rooms uninhabitable; for
others, the smokedrift is a nuisance that
carries health concerns.  The Center also
fields inquiries from landlords and
management companies considering
adoption of a smokefree building policy;
similar inquiries come from condominium
boards.
This summer the Center will launch an
effort to educate landlords, tenants,
condominium owners, and condominium
boards about each group’s legal rights and
responsibilities regarding smokedrift in
multi-unit housing.  The campaign will
include a comprehensive website, an
educational brochure for tenants and
another for landlords, model policies for
management companies and condominium
boards, and a listing of available smokefree
housing.
The Center is also working with the
Maryland Park Service to recommend to the
Parks Commission a policy concerning
tobacco use on all state park property.
While some local jurisdictions in Maryland
have adopted smokefree policies for their
recreation and park properties and some
states have done so for state park property,
Maryland does not have a tobacco use
policy for state parks.
In light of the
environmental, fire
safety, and health
concerns associated
with tobacco use in
parks, Center staff
believe the state should
adopt a comprehensive
policy.  Center
Director Kathleen
Dachille recently made
a presentation to the
State Parks Commission on this issue.
Finally, the Center is preparing a policy
paper, along with recommendations for
local governments, on dealing with the
health implications of hookah bars.  These
establishments offer patrons the
opportunity to purchase, and smoke in a
water pipe, flavored tobacco known as
shisha.  Most hookah establishments also
serve alcohol or food and so will likely be
subject to the clean indoor air restrictions
that go into effect on February 1, 2008.  It
is possible, however, for a hookah
establishment to meet the tobacconist
exception in that law or to apply
successfully for a waiver.  Hookah smoking
presents health risks in addition to those
associated with smoking and secondhand
smoke, including the transmission of
communicable diseases from sharing of a
stem or pipe.  The Center plans to offer
local health departments and legislatures
regulatory or legislative proposals that are
designed to diminish the health risks
associated with hookah use.
Tobacco Center:  Litigation
Another critical function of the
Tobacco Center is providing legal
assistance to lawyers representing local
governments.  This assistance can take
several forms, including training in
statistics and epidemiology essential to
making persuasive arguments about
causation of illness or injury from tobacco
products, mooting oral arguments for
attorneys preparing to argue tobacco
cases, and drafting briefs or arranging for
amicus briefs for attorneys representing
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local governments or community
coalitions.
The Center also monitors and provides
high level litigation support to state
governments involved in tobacco litigation.
Recently, Center Director Dachille was
appointed as a Special Assistant Attorney
General in Maryland to work in support of
the Vermont Attorney General’s case against
R.J. Reynolds for the marketing of the
Eclipse cigarette.  Eclipse has been marketed
as a cigarette posing less risk of lung cancer
and emphysema and as emitting significantly
less secondhand smoke than traditional
cigarettes.  The Vermont Attorney General
sued Reynolds alleging that the marketing
of Eclipse is deceptive and in violation of
the Vermont Consumer Fraud Statute and
the Master Settlement Agreement.  More
than a dozen states are lending litigation
support; the Center has joined that support
team through Dachille’s appointment and
uses invaluable and plentiful student
research skills to support the team.
Conferences
The Center has sponsored a number of
conferences, workshops and symposia in
the five years since its inception, including
noteworthy conferences on new tobacco
products, fire-safe cigarettes and youth
sales enforcement.  On April 20, the
Center sponsored a national one-day
conference on so-called “reduced harm”
or “reduced-exposure” tobacco products.
Participants in this conference tackled the
question of how the public health
community should respond to these
products and the legal issues surrounding
their marketing and use. (See article, p. 5.)
Endnotes
1 Secondhand Smoke and Casinos,
Micah Berman & Caris Post, available at
http://tclconline.org/resourcesTCLC.html.
2 Legal Options for Condominium Owners
Exposed to Secondhand Smoke, Susan
Schoenmarklin, available at
 http://tclconline.org/resourcesTCLC.html.
3 Public Health Policy for Internet Cigarette
Retailers. Christopher Banthin, available at
 http://tclconline.org/resourcesTCLC.html.
4 Local Land Use Regulation for the Location
and Operation of Tobacco Retailers,
Randolph Kline, available at http://
tclconline.org/resourcesTCLC.html.
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first national legal conference on the
issue.  Rothenberg’s research was later
incorporated into both New York state
policy and CDC recommendations on
HIV/AIDS partner notification.
Rothenberg spoke to the University of
Capetown audience about the three
analytical principles that emerged from
her research regarding women with HIV/
AIDS: interdependence, gender relevance
and shifting paradigms.  She explained
that her research led her to understand
that public health issues cannot be
studied in isolation from each other; that
gender does matter when making public
health policy; and, finally, that policy
makers need to understand and adapt to
shifting paradigms if their work is to be
effective.  One example of a shifting
paradigm that Rothenberg discussed was
the change in the United States from
perceiving HIV/AIDS as a death sentence
to a chronic disease and the policy
implications of this shift in perception.
She urged the South African audience to
employ these analytical principles to their
future research on the ways in which
HIV/AIDS is both a trigger and result of
domestic violence.
*Students pictured were externing in
South Africa for the semester.
hospitals in a state. With both surveillance
screening and mandatory reporting of
nosocomial infections individual test
results and aggregate data will be created
that could be used against a hospital in a
civil law suit based on damages resulting
from a nosocomial infection.
To address these legal issues, Professor
Diane Hoffmann was invited to speak in
April at the annual meeting of the Society
for Healthcare Epidemiology of America
(SHEA).  In her talk, “Law & Order: the
Changing Legal Landscape Around
Healthcare Associated Infections,”
Hoffmann discussed the success of
nosocomial infection lawsuits in the nation’s
courts, defenses to such actions, and
whether state and federal laws confer any
statutory protection over the use of
information generated by mandatory
reporting or surveillance screening in civil
lawsuits.  She also addressed the likelihood
that the standard of care with regard to the
prevention of nosocomial infections will
rise given evidence that adoption of certain
procedures can significantly reduce the
incidence of these infections.  Hoffmann
concluded that mandatory reporting
statutes and pre-admission screening for
nosocomial diseases may represent a risk to
hospitals in the civil litigation arena but, on
an optimistic note, noted that such
reporting and screening is also likely to
result in fewer cases of nosocomial
infection, and therefore, fewer lawsuits.
Hoffmann will be discussing this issue at the
upcoming Health Law Professors
Conference at Boston University in June.
Endnotes
1 Hidron, Alice, et al., Clinical Infectious
Diseases 2005; 41: 167-9.
2 Davis, K.A., et al., Clinical Infectious
Diseases 2004; 39: 776-82.
3 MRSA: An Action Network Briefing,
BBC.  Available at
http://www.bbc.co.uk/dna/
actionnetwork/A2836550.
20  Law & Health Care Newsletter – www.law.umaryland.edu/specialty/maryhealth/index.asp
Non-Profit Org.
U.S. Postage
PAID
Baltimore, MD
Permit No. 2439
LAW & HEALTH CARE PROGRAM
UNIVERSITY OF MARYLAND SCHOOL OF LAW
500 WEST BALTIMORE STREET
BALTIMORE, MD 21201
Comments and letters should be
forwarded to the above address.
views of five Framework Convention
Alliance members by reading prepared
statements.  Alva spoke on behalf of
Action on Smoking & Health (UK) and
Lauren on behalf of the University of
California at San Francisco.  According to
Lauren, her experiences in Brazil have
given her “a greater understanding of the
issues associated with tobacco cultivation
and the inner workings of implementing a
global public health treaty.”  Bostic
commented that, in addition to being an
incredibly enriching experience for
students in the short term, including
students in high-level meetings trains them
to enter the tobacco control community
upon graduation from law school.
Recently, Vestal worked with the
Director of the Law & Health Care
Program, Diane Hoffmann, and Program
Coordinator, Virginia Rowthorn, to set
up an externship program in the TFI for
University of Maryland law school
students.  Under this new externship
placement, students will work with
Vestal on various legal and regulatory
issues relating to international tobacco
control.  Although other L&HCP
students have had externships at WHO in
the office of the General Counsel, the
first student to work as an extern with
the Tobacco Free Initiative left for
Geneva this month.  Vestal says she is
very grateful to “the many people who
have opened doors for me,” and this has
made her committed to opening doors to
qualified and motivated University of
Maryland law students. 
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